Skip to content
2000
Volume 6, Issue 2
  • ISSN: 1871-5206
  • E-ISSN: 1875-5992

Abstract

One category of boron neutron capture therapy (BNCT) agents that has received extensive attention during recent years is 3-carboranyl thymidine analogues (3CTAs). These molecules are phosphorylated to the corresponding 5´- monophosphates by human thymidine kinase 1 (TK1), an enzyme that is up-regulated in dividing malignant cells. Thus, these phosphorylated molecules are selectively entrapped in tumor cells due to the acquired negative charge. This review will analyze design strategies applied for the synthesis of boron-containing nucleosides in general and in particular reference to 3CTAs. Results of biological studies with these molecules will be discussed.

Loading

Article metrics loading...

/content/journals/acamc/10.2174/187152006776119171
2006-03-01
2025-04-09
Loading full text...

Full text loading...

/content/journals/acamc/10.2174/187152006776119171
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test